{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:44:10Z","timestamp":1761101050876},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T00:00:00Z","timestamp":1304899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T00:00:00Z","timestamp":1304899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1038\/bmt.2011.101","type":"journal-article","created":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T10:48:47Z","timestamp":1304938127000},"page":"411-415","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["CT60 single-nucleotide polymorphism as a surrogate marker for donor lymphocyte infusion outcome after allogeneic cell transplantation for acute leukemia"],"prefix":"10.1038","volume":"47","author":[{"given":"Y","family":"Metaxas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Bertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Spyridonidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Spyroupoulou-Vlachou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Porzelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Finke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,9]]},"reference":[{"key":"BFbmt2011101_CR1","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V96.8.2712","volume":"96","author":"F Dazzi","year":"2000","unstructured":"Dazzi F, Szydlo RM, Cross NCP, Craddock C, Kaeda J, Kanfer E et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712\u20132716.","journal-title":"Blood"},{"key":"BFbmt2011101_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","volume":"15","author":"RH Collins","year":"1997","unstructured":"Collins RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433\u2013444.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011101_CR3","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"C Schmid","year":"2007","unstructured":"Schmid C, Labopin M, Nagler A, Bornh\u00e4user M, Finke J, Fassas A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 25: 4938\u20134945.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011101_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1089\/152581602753658457","volume":"11","author":"S Slavin","year":"2002","unstructured":"Slavin S, Morecki S, Weiss L, Or R . Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and non-malignant diseases in conjunction with allogeneic stem cell transplantation. J Hemat Stem Cell Res 2002; 11: 265\u2013276.","journal-title":"J Hemat Stem Cell Res"},{"key":"BFbmt2011101_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.0105-2896.2005.00249.x","volume":"204","author":"SC Gough","year":"2005","unstructured":"Gough SC, Walker LS, Sansom DM . CTLA4 gene polymorphism and autoimmunity. Immunol Rev 2005; 204: 102\u2013115.","journal-title":"Immunol Rev"},{"key":"BFbmt2011101_CR6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","volume":"270","author":"P Waterhouse","year":"1995","unstructured":"Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270: 985\u2013988.","journal-title":"Science"},{"key":"BFbmt2011101_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/blood-2007-01-069781","volume":"110","author":"A P\u00e9rez-Garc\u00eda","year":"2007","unstructured":"P\u00e9rez-Garc\u00eda A, C\u00e1mara R, Rom\u00e1n-G\u00f3mez J, Jim\u00e9nez-Velasco A, Encuentra M, Nieto JB et al. CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA- identical sibling donors. Blood 2007; 110: 461\u2013467.","journal-title":"Blood"},{"key":"BFbmt2011101_CR8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature01621","volume":"423","author":"H Ueda","year":"2003","unstructured":"Ueda H, Howson JM, Esposito L, Esposito L, Heward J, Snook H et al. Association of the T-cell regulatory gene CTLA-4 with susceptibility to autoimmune disease. Nature 2003; 423: 506\u2013511.","journal-title":"Nature"},{"key":"BFbmt2011101_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/sj.gene.6364211","volume":"6","author":"SM Anjos","year":"2005","unstructured":"Anjos SM, Shao W, Marchand L, Polychronakos C . Allelic effects on gene regulation at the autoimmunity-predisposing CTLA4 locus: a re-evaluation of the 3\u2032 +6230G>A polymorphism. Genes Immunity 2005; 6: 305\u2013311.","journal-title":"Genes Immunity"},{"key":"BFbmt2011101_CR10","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on acute GVHD grading. BMT 1995; 15: 825\u2013828.","journal-title":"BMT"},{"key":"BFbmt2011101_CR11","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/leu.2008.339","volume":"23","author":"A P\u00e9rez-Garc\u00eda","year":"2009","unstructured":"P\u00e9rez-Garc\u00eda A, Brunet S, Berlanga JJ, Tormo M, Nomdedeu J, Guardia R et al. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy. Leukemia 2009; 23: 486\u2013491.","journal-title":"Leukemia"},{"key":"BFbmt2011101_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1479-5876-8-108","volume":"8","author":"H Gogas","year":"2010","unstructured":"Gogas H, Dafni U, Koon H, Spyroupoulou-Vlachou M, Metaxas Y, Buchbinder E et al. Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A\/98 multicenter trial. J Trans Med 2010; 8: 108\u2013112.","journal-title":"J Trans Med"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2011101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2011101","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2011101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T13:19:01Z","timestamp":1648041541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2011101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,9]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["BFbmt2011101"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2011.101","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,9]]},"assertion":[{"value":"6 October 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}